

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Cervix Cancer

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education

1. Massad LS. Assessing disease extent in women with bulky or clinically evident metastatic cervical cancer: yield of pretreatment studies. *Gynecol Oncol.* 2000;76(3):383–387.
<https://pubmed.ncbi.nlm.nih.gov/10684715/>
2. Havrilesky LJ. FDG-PET for management of cervical and ovarian cancer. *Gynecol Oncol.* 2005;97(1):183–191. <https://pubmed.ncbi.nlm.nih.gov/15790456/>
3. Amit A. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. *Gynecol Oncol.* 2006;100(1):65–69. <https://pubmed.ncbi.nlm.nih.gov/16269172/>
4. Landoni F. Class II vs. class III radical hysterectomy in stage IB–IIA cervical cancer: a prospective randomized study. *Gynecol Oncol.* 2001;80(1):3–12. <https://pubmed.ncbi.nlm.nih.gov/11136561/>
5. Landoni F. Randomised study of radical surgery vs. radiotherapy for stage Ib–IIa cervical cancer. *Lancet.* 1997;350(9077):535–540. <https://pubmed.ncbi.nlm.nih.gov/9284774/>
6. Wolf JK. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. *Obstet Gynecol.* 1996;88(1):82–86. <https://pubmed.ncbi.nlm.nih.gov/8684768/>
7. Greer BE. Stage IA2 squamous carcinoma of the cervix: difficult diagnosis and therapeutic dilemma. *Am J Obstet Gynecol.* 1990;162(6):1409–1411. <https://pubmed.ncbi.nlm.nih.gov/2360573/>
8. Sutton G. Ovarian metastasis in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1992; 166(1):50–53. <https://pubmed.ncbi.nlm.nih.gov/1733218/>
9. Whitney CW. The abandoned radical hysterectomy: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2000;79(3):350–356. <https://pubmed.ncbi.nlm.nih.gov/11104604/>

10. Cosin JA. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. *Cancer*. 1998;82(11):2241–2248. <https://pubmed.ncbi.nlm.nih.gov/9610705/>
11. Ziebarth AJ. Completed vs. aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemo-radiation therapy. *Gynecol Oncol*. 2012;126(1):69–72. <https://pubmed.ncbi.nlm.nih.gov/22484400/>
12. Potter ME. Early invasive cervical cancer with pelvic lymph node involvement: to complete or not to complete radical hysterectomy? *Gynecol Oncol*. 1990;37(1):78–81. <https://pubmed.ncbi.nlm.nih.gov/2323617/>
13. Magrina JF. The prognostic significance of pelvic and aortic lymph node metastasis. *CME J Gynecol Oncol*. 2001;6(3):302–306. <https://www.scopus.com/record/display.uri?eid=2-s2.0-0035679672&origin=inward&txGid=c0db92089dc2c96c5404b10c6a86b220>
14. Goff BA. Impact of surgical staging in women with locally advanced cervical cancer. *Gynecol Oncol*. 1999;74(3):436–442. <https://pubmed.ncbi.nlm.nih.gov/10479506/>
15. Smith KB. Postoperative radiotherapy for cervix cancer incidentally discovered after a simple hysterectomy for either benign conditions or noninvasive pathology. *Am J Clin Oncol*. 2010;33(3):229–232. <https://pubmed.ncbi.nlm.nih.gov/19806037/>
16. Rose PG. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010;117(2):270–275. <https://pubmed.ncbi.nlm.nih.gov/20181381/>
17. Piver MS. Five classes of extended hysterectomy for women with cervical cancer. *Obstet Gynecol*. 1974;44:265–272. <https://pubmed.ncbi.nlm.nih.gov/4417035/>
18. Boran N. Scalene lymph node dissection in locally advanced cervical carcinoma: is it reasonable or unnecessary? *Tumori*. 2003;89(2):173–175. <https://pubmed.ncbi.nlm.nih.gov/12841666/>
19. Chambers SK. Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. *Int J Radiat Oncol Biol Phys*. 1991;20(6):1305–1308. <https://pubmed.ncbi.nlm.nih.gov/2045304/>

20. Sedlis A. A randomized trial of pelvic radiation therapy vs. no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1999;73(2):177–183.
<https://pubmed.ncbi.nlm.nih.gov/10329031/>
21. Delgado G. Prospective surgical-pathological study of disease free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1990;38(3):352–357. <https://pubmed.ncbi.nlm.nih.gov/2227547/>
22. Peters WA. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol.* 2000;18(8):1606–1613. <https://pubmed.ncbi.nlm.nih.gov/10764420/>
23. Obermair A. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. *Int J Gynecol Cancer.* 2003;13(5):633–639.
<https://pubmed.ncbi.nlm.nih.gov/14675347/>
24. Thomas G. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs. above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. *Gynecol Oncol.* 2008;108(2):317–325.
<https://pubmed.ncbi.nlm.nih.gov/18037478/>
25. Long HJ III. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *J Clin Oncol.* 2005;23(21):4626–4633.
<https://pubmed.ncbi.nlm.nih.gov/15911865/>
26. Russell AH. Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract. *Gynecol Oncol.* 1987;27(2):226–232. <https://pubmed.ncbi.nlm.nih.gov/3570061/>
27. Monk BJ. Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. *Gynecol Oncol.* 1994;52(2):222–228.
<https://pubmed.ncbi.nlm.nih.gov/8314143/>

28. Delgado D. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol*. 1989;35(3):314–320.
<https://pubmed.ncbi.nlm.nih.gov/2599466/>
29. Keys HM. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. *Gynecol Oncol*. 2003;89(3):343–353. <https://pubmed.ncbi.nlm.nih.gov/12798694/>
30. Rotman M. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: a follow-up of a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 2006;65(1):169–176. <https://pubmed.ncbi.nlm.nih.gov/16427212/>
31. Keys HM. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med*. 1999;340(15):1154–1161.
<https://pubmed.ncbi.nlm.nih.gov/10202166/>
32. Whitney CW. Randomized comparison of fluorouracil plus cisplatin vs. hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol*. 1999;17(5):1339–1348. <https://pubmed.ncbi.nlm.nih.gov/10334517/>
33. Rose PG. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*. 1999;340(15):1144–1153. <https://pubmed.ncbi.nlm.nih.gov/10202165/>
34. Monk BJ, Wang J, Im S. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. *Gynecol Oncol*. 2005;96(3):721–728.
<https://pubmed.ncbi.nlm.nih.gov/15721417/>
35. Varia MA. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 1998;42(5):1015–1023. <https://pubmed.ncbi.nlm.nih.gov/9869224/>

36. Lanciano R. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 2005;23(33):8289–8295. <https://pubmed.ncbi.nlm.nih.gov/16230678/>
37. Rotman M. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. *JAMA.* 1995;274(5):387–393. <https://pubmed.ncbi.nlm.nih.gov/7616634/>
38. Morris M. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation in high-risk cervical cancer. *N Engl J Med.* 1999;340(15):1137–1143. <https://pubmed.ncbi.nlm.nih.gov/10202164/>
39. Eifel PJ. Pelvic irradiation with concurrent chemotherapy vs. pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. *J Clin Oncol.* 2004;22(5):872–880. <https://pubmed.ncbi.nlm.nih.gov/14990643/>
40. Pearcey R. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol.* 2002;20(4):966–972. <https://pubmed.ncbi.nlm.nih.gov/11844818/>
41. Moore DH. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol.* 2004;22(15):3113–3119. <https://pubmed.ncbi.nlm.nih.gov/15284262/>
42. Monk BJ. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2009;27(28):4649–4655. <https://pubmed.ncbi.nlm.nih.gov/19720909/>
43. Duenas-Gonzales A. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin vs. concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. *J Clin Oncol.* 2011;29(13):1678–1685. <https://pubmed.ncbi.nlm.nih.gov/21444871/>

44. Bentivegna, E., Gouy, S., Maulard, A., Chargari, C., Leary, A., & Morice, P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. *Lancet Oncol* 2016, 17(6), e240-e253. <https://pubmed.ncbi.nlm.nih.gov/27299280/>
45. Lécuru, F., Mathevet, P., Querleu, D., Leblanc, E., Morice, P., Daraï, E., ... Dargent, D. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. *J Clin Oncol* 2011, 29(13), 1686-1691. <https://pubmed.ncbi.nlm.nih.gov/21444878/>
46. Cibula, D., Abu Rustum, N. R., Benedetti Panici, P., Köhler, C., Raspagliesi, F., Querleu, D., & Morrow, C. P. New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. *Gynecol Oncol* 2011, 122(2), 264-268. <https://pubmed.ncbi.nlm.nih.gov/21592548/>
47. Leath, C. A., Straughn, J. M. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. *Gynecol Oncol* 2013, 129(1), 251-257. <https://pubmed.ncbi.nlm.nih.gov/23280089/>
48. Kadkhodayan, S., Hasanzadeh, M., Treglia, G., Azad, A., Yousefi, Z., Zarifmahmoudi, L., & Sadeghi, R.. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. *European J Surg Oncol* 2015, 41(1), 1-20. <https://pubmed.ncbi.nlm.nih.gov/25454828/>
49. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., ... Leblanc, E.. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. *J Clin Oncol* 2013, 31(24), 3026-3033. <https://pubmed.ncbi.nlm.nih.gov/23857967/>
50. Ramirez, P. T., Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., ... Obermair, A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. *N Engl J Med* 2018, 379(20), 1895-1904. <https://pubmed.ncbi.nlm.nih.gov/30380365/>

51. Melamed, A., Margul, D. J., Chen, L., Keating, N. L., Del Carmen, M. G., Yang, J., ... Rauh Hain, J. A.. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. *N Engl J Med* 2018, 379(20), 1905-1914. <https://pubmed.ncbi.nlm.nih.gov/30379613/>
52. Frenel, J., Le Tourneau, C., O'Neil, B., Ott, P. A., Piha Paul, S. A., Gomez Roca, C., ... Varga, A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. *J Clin Oncol* 2017, 35(36), 4035-4041. <https://pubmed.ncbi.nlm.nih.gov/29095678/>
53. Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., ... Monk, B. J. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). *Lancet* 2017, 390(10103), 1654-1663. <https://pubmed.ncbi.nlm.nih.gov/28756902/>